201286-95-5

Basic information

• Product Name: 3-Methyl-1H-indazole-6-carboxylic acid methyl ester
• Synonyms: 3-Methyl-1H-indazole-6-carboxylic acid methyl ester
• CAS NO: 201286-95-5
• Molecular Formula: C₁₀H₁₀N₂O₂
• Molecular Weight: 190.1986
• Mol File: 201286-95-5.mol

Chemical Properties

• Boiling Point: 355.5±22.0 °C(Predicted)
• Appearance: /
• Density: 1.274±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 12.82±0.40(Predicted)
• CAS DataBase Reference: 3-Methyl-1H-indazole-6-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Methyl-1H-indazole-6-carboxylic acid methyl ester(201286-95-5)
• EPA Substance Registry System: 3-Methyl-1H-indazole-6-carboxylic acid methyl ester(201286-95-5)

Safety Data

• Hazardous Substances Data: 201286-95-5(Hazardous Substances Data)

Upstream product

• 24812-93-9 3-amino-4-ethylbenzoic acid methyl ester 
• 5129-23-7 3-Amino-4-ethyl benzoic acid 
• 51885-79-1 4-ethyl-3-nitro-benzoic acid methyl ester 
• 619-64-7 p-ethylbenzoic acid 
• 103440-95-5 4-Ethyl-3-nitrobenzoic acid 
• 108-24-7 acetic anhydride 
• 201286-96-6 3-methyl-indazole-6-carboxylic acid 
• 67-56-1 methanol 

Downstream Products

• 219764-07-5 6-carboxy-1-(2-chloro-4-phenylbenzyl)-3-methyl-1H-indazole 
• 219763-47-0 6-carboxy-1-(2,4-dichlorobenzyl)-3-methyl-1H-indazole 
• 219764-09-7 1-(4-bromo-2-chlorobenzyl)-6-carboxy-3-methyl-1H-indazole 
• 201286-94-4 Methyl 1-benzyl-3-methyl-1 H-indazole-6-carboxylate 

Relevant articles and documents

GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS

The invention relates to a compound of a general formula (I): wherein A represents a linking group; Ar1 represents a group formed from an aromatic ring; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkoxy group, a cyclo-C3-C6 alkyloxy group, a C2-C7 alkanoyl group, a halo-C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, a halo-C2-C7 alkoxycarbonyl group, a cyclo-C3-C6 alkyloxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; a C1-C6 alkyl group optionally having substituent(s); an aryl or heterocyclic group optionally having substituent(s); or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nitrogen atom or a methine group; and V represents an oxygen atom, a sulfur atom or an imino group. The compound of the invention is useful as therapeutical agents for various ACC-related diseases.

Sulfonamide compounds and medicinal use thereof

A sulfonamide compound of the formula (I):R 1 --SO 2 NHCO--A--R 2 (I)wherein R 1 is alkyl, alkenyl, alkynyl and the like; A is an optionally substituted heteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R 2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.

Substituted azabicyclic compounds

This invention is directed to certain physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates of the compounds of formula (I) and N-oxides thereof, and their prodrugs. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.